Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell …
L Dong, ZY Gao, LJ Chang, Y Liang… - Journal of pediatric …, 2010 - journals.lww.com
This report describes a safe and effective therapy through adoptive transfer of donor
cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3
to 10 years of age, suffering from hematologic diseases received haploidentical
transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2
patients developed CMV-interstitial pneumonitis or interstitial inflammation after
transplantation. Tapering down the dose of immunosuppressives together with intensive …
cytomegalovirus (CMV)/Epstein-Barr virus (EBV) immune effector cells. The patients, from 3
to 10 years of age, suffering from hematologic diseases received haploidentical
transplantation. All 3 patients developed varying levels of viremia from days 13 to 31 and 2
patients developed CMV-interstitial pneumonitis or interstitial inflammation after
transplantation. Tapering down the dose of immunosuppressives together with intensive …